Neoolife includes an international, multidisciplinary team with more than 130 years of cumulative experience in biomedical technology and device therapy. Our business team has a recognized track of leadership in both large corporations and start-ups.

Their worldwide recognized bio/chemical/mechanical engineers and cardiovascular physicians have a long-lasting involvement in the research & development, clinical, and academic fields of cardiovascular disease. They focus on tissue-engineered Biomimetic Heart Valves (BMHV) and tissue-engineered Biomimetic Cardiovascular Patches (BMCP) that enable endogenous in situ tissue regeneration. Thier technology is used for percutaneous and surgical applications.

Neoolife is also developing unique solutions for the percutaneous treatment of heart valve disease, i.e., tricuspid valve regurgitation.

Neoolife polymeric tissue-engineered biomimetic products are durable, non-thrombogenic, and resistant to calcification.

The University of Pittsburgh is a top-ranked, public institution in Pennsylvania and a member of the Association of American Universities of leading research universities. With their discoveries, they are recognized as one of the most innovative universities in the world. They invent the paths of the future and forge ahead.

Pitt is a member of the Association of American Universities (AAU), which comprises 62 preeminent doctorate-granting research institutions in North America.

The McGowan Institute for Regenerative Medicine at the University of Pittsburgh seeks to be a national and international leader in regenerative medicine to address organ and tissue failure. McGowan researchers are dedicated to finding groundbreaking solutions in the fields of tissue engineering, cellular therapies, and medical devices to address human health issues of societal importance.

The McGowan Institute’s goal is to use the vast field of regenerative medicine to improve patient outcomes and quality of life. Their institute’s 250 interdisciplinary faculty members across the University of Pittsburgh’s campus and with other academic, industry and government partners are driven to conceptualize, innovate, develop, and commercialize regenerative medicine technologies for societal benefit.